Cost-Effectiveness of Dopamine Agonists and Monoamine Oxidase B Inhibitors in Early Parkinson's Disease.
Emma McIntoshSeamus KentAlastair GrayCarl E ClarkeAdrian WilliamsCrispin JenkinsonNatalie IvesSmitaa PatelCaroline RickKeith WheatleyRichard Graynull nullPublished in: Movement disorders : official journal of the Movement Disorder Society (2021)
Initial treatment with levodopa is highly cost-effective compared with levodopa-sparing therapies. Monoamine oxidase type B inhibitors, as initial levodopa-sparing therapy was more cost-effective, with similar quality-adjusted life-years but lower costs than dopamine agonists. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.